
CurveBeam AI wins first China order for four scanners
Key points
- CurveBeam AI has received its first order from China, for four of its HiRise weight-bearing CT scanners.
- The order comes from its exclusive Chinese distribution partner, Weiying/Wego Orthopedics, after Chinese regulators cleared the scanner in October.
- The company also expects a A$1 million milestone investment from its partner this quarter.
CurveBeam AI (ASX:CVB) has received its first order in China, for four HiRise weight-bearing CT scanners, from its distribution partner Weiying/Wego Orthopedics.
The order follows clearance of the scanner by China’s National Medical Products Administration, which the company announced on 13 October 2026.
“Receiving our first order for four HiRise™ systems in China is an important commercial step for CurveBeam,” said CurveBeam AI CEO Greg Brown.
The company also expects to receive a A$1 million milestone investment from its partner this quarter, at A$0.405 a share, though it said banking processes could cause delays.
CurveBeam said the order moves its China partnership from agreement to commercial sales, under a long-term exclusive distribution deal signed in October 2025. Following the announcement the CurveBeam AI share price was up at $0.018.
The distribution agreement covers mainland China, Hong Kong, Macau and Taiwan.
HiRise scans the lower limbs while patients stand and bear their own weight, which helps orthopaedic specialists assess conditions in the foot, ankle and knee.
Frequently asked questions
More from Australia
Amplitude targets last east coast gas well in bid to boost Australian supply
Manhattan Gold extends Jaws gold strike beyond 2km
Sierra Nevada Gold hits 57m of gold at As Safra
Sunrise Energy Metals clears FIRB hurdle for Nasdaq move
Elementos starts 3,600m drilling at Cleveland tin project
Dexus Industria chair Jennifer Horrigan retires after 14 years

